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ABSTRACT Cystic fibrosis (CF) is a fatal genetic disorder associated with defective hydration 
of lung airways due to the loss of chloride transport through the CF transmembrane conduc-
tance regulator protein (CFTR). CFTR contains two membrane-spanning domains (MSDs), two 
nucleotide-binding domains (NBDs), and a regulatory domain, and its channel assembly re-
quires multiple interdomain contacts. The most common CF-causing mutation, F508del, oc-
curs in NBD1 and results in misfolding and premature degradation of F508del-CFTR. VX-809 
is an investigational CFTR corrector that partially restores CFTR function in people who are 
homozygous for F508del-CFTR. To identify the folding defect(s) in F508del-CFTR that must 
be repaired to treat CF, we explored the mechanism of VX-809 action. VX-809 stabilized an 
N-terminal domain in CFTR that contains only MSD1 and efficaciously restored function to 
CFTR forms that have missense mutations in MSD1. The action of VX-809 on MSD1 appears 
to suppress folding defects in F508del-CFTR by enhancing interactions among the NBD1, 
MSD1, and MSD2 domains. The ability of VX-809 to correct F508del-CFTR is enhanced when 
combined with mutations that improve F508del-NBD1 interaction with MSD2. These data 
suggest that the use of VX-809 in combination with an additional CFTR corrector that sup-
presses folding defects downstream of MSD1 may further enhance CFTR function in people 
with F508del-CFTR.
INTRODUCTION
Cystic fibrosis (CF) is caused by the loss of epithelial chloride trans-
port due to mutations in the CF transmembrane conductance regu-
lator (CFTR) gene that encodes the CFTR protein (Riordan et al., 
1989a). The CFTR protein is a chloride channel that is normally pres-
ent at the cell surface of epithelial cells, where it regulates salt, fluid, 
and pH balance in multiple organs (Quinton, 1983, 2008; Boucher, 
2007). In people with CF, the loss of chloride transport due to de-
fects in the CFTR protein results in the accumulation of thick, sticky 
mucus in the bronchi of the lungs, loss of exocrine pancreatic func-
tion, impaired intestinal absorption, reproductive dysfunction, and 
elevated sweat chloride concentration (Boucher, 2007; Castellani 
et al., 2008).
CFTR is a 1480–amino acid ATP-binding cassette transporter 
protein that contains two membrane-spanning domains (MSD1 and 
MSD2) that form the chloride channel pore, two nucleotide-binding 
domains (NBD1 and NBD2) that bind and hydrolyze ATP to open 
and close the channel pore (channel gating), and a regulatory do-
main with several protein kinase A phosphorylation sites (Ikuma and 
Welsh, 2000; Rowe et al., 2005). Formation of the CFTR channel 
requires the coordinated folding and assembly of the individual 
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Okiyoneda et al., 2004; Farinha and Amaral, 2005; Lukacs and 
Verkman, 2012); identify defective interactions between MSD1, 
NBD1, and MSD2 as an underlying cause of premature degradation 
of F508del-CFTR (Younger et al., 2006; Cui et al., 2007; Du and 
Lukacs, 2009); and identify MSD2 as the site of action of the CFTR 
corrector Corr-4a. Coexpression of nonoverlapping N- and C-termi-
nal CFTR fragments in cells led to an increase in chloride transport, 
suggesting these individual CFTR fragments were able to coassem-
ble and form a functional CFTR channel (Csanady et al., 2000).
The shortest-length CFTR fragment affected by VX-809 was 
CFTR 375, which contains only MSD1 (Figure 1C). As expected, 
longer-length CFTR fragments were also increased by VX-809, in-
cluding CFTR fragments that contained NBD1 with the F508del mu-
tation (Figures 1D and S1). VX-809 did not increase the stability of 
CFTR 837–1480, which contains only MSD2 and NBD2 (Figure S1). 
In dose-response studies using CFTR 380, the maximal effective 
concentration of VX-809 was 3 μM, which is similar to that observed 
for full-length F508del-CFTR (Figure 1E; Van Goor et al., 2011). In 
pulse–chase studies, the half-lives of CFTR 375, CFTR 380, CFTR 
430, and CFTR 653 were increased compared with untreated con-
trols (Figures 1F and S1), indicating that the increase in steady-state 
accumulation caused by VX-809 is associated with an increase in the 
stability of the individual CFTR fragments. The inability of VX-809 to 
increase the accumulation of CFTR370 suggests that VX-809 does 
not act as a proteasome inhibitor, as bortezomib was able to in-
crease the stability of this CFTR fragment (Figure 1B). Taken to-
gether, these data indicate that the shortest-length CFTR require-
ment for VX-809 action contains only MSD1. Moreover, these data 
suggest that VX-809 increases the stability of the protein conforma-
tion of MSD1 and, as a consequence, its resistance to ERAD.
VX-809 alters the protein conformation of MSD1
To test whether VX-809 alters the protein conformation of MSD1 to 
result in a more stable folded form that is resistant to ERAD, we 
tested the compound’s ability to protect a subdomain of MSD1 from 
proteolytic digestion, using limited proteolysis of CFTR in cell ex-
tracts made with the nonionic detergent Triton X-100 (Figure 2). This 
technique, based on the premise that folded proteins are more com-
pact and therefore typically more resistant to proteolytic digestion 
than unfolded or partially folded proteins, has been used to probe 
differences in protein folding between wild-type and F508del-CFTR, 
as well as between uncorrected and VX-809–corrected F508del-
CFTR (Lukacs et al., 1994; Van Goor et al., 2011). For these studies, 
CFTR 380 was used, as it was the most stable CFTR fragment follow-
ing treatment with VX-809. In cells expressing CFTR 380 or full-
length F508del-CFTR, treatment with VX-809 increased the libera-
tion of a protease-resistant species with an apparent molecular 
weight of 22 kDa that was detected with an antibody directed 
against the N-terminal tail of CFTR. Taken together, data presented 
in Figures 1 and 2 suggest that VX-809 alters the protein conforma-
tion of MSD1 to suppress folding defects in F508del-CFTR.
Residue 374 and 375 help MSD1 fold to a conformation 
that is stabilized by VX-809
The above data indicate that residues 374–375 are required for 
sensitivity of MSD1 fragments to VX-809, whereas residues 376–380 
appear to aid in folding of MSD1 to a more stable form (Figure 1C). 
Deletion of residues 371–375 from full-length CFTR caused a severe 
folding defect, resulting in little to no mature form (C-band) and 
eliminating sensitivity to VX-809 (Figure 3A). Similarly, Δ371–375 
CFTR 380 accumulated at 10% of CFTR 380 levels and was insensi-
tive to VX-809 (Figure 3B). Thus residues 371–375 are important for 
2012). Each MSD is composed of six transmembrane segments 
(TM1–6 and TM7–12) that are associated with long α-helical cytoso-
lic extensions known as coupling helices, which are connected by 
intracellular loops (ICLs). Contact formation between the ICLs and 
NBDs is critical for the proper assembly and Cl− channel function of 
CFTR (Anderson et al., 1991; Riordan et al., 1989b; Riordan, 2008).
The most common CFTR mutation in patients with CF is the de-
letion of phenylalanine at position 508 (F508del) in NBD1. Normally, 
F508 is critical for folding and assembly of native CFTR, as its back-
bone and side chain participate in the formation of a network of in-
terdomain contacts that stabilizes interactions between NBD1 and 
ICL1 of MSD1 and ICL4 of MSD2 (Mornon et al., 2008; Serohijos 
et al., 2008). In the absence of F508, folding of the individual CFTR 
subdomains is initiated, but channel assembly is arrested at an inter-
mediate stage (Lukacs et al., 1994; Younger et al., 2006; Rosser 
et al., 2008; Serohijos et al., 2008). This leads to accumulation of an 
ensemble of nonnative F508del-CFTR biogenic intermediates that 
are rapidly targeted for proteasomal degradation by the endoplas-
mic reticulum quality control machinery (Meacham et al., 2001; 
Younger et al., 2006; Grove et al., 2011). As a result, little to no 
F508del-CFTR is delivered to the cell surface, and CFTR chloride 
transport activity is abolished.
A potential therapeutic strategy to treat CF would be the use of 
small-molecule compounds that increase the amount of F508del-
CFTR delivered to the cell surface. Such compounds are known as 
CFTR correctors. The investigational CFTR corrector, VX-809, in-
creases the delivery of functional F508del-CFTR to the cell surface, 
resulting in partial restoration of chloride transport in cultured hu-
man bronchial epithelial cells derived from people with CF who are 
homozygous for F508del-CFTR. In vitro, the amount of chloride 
transport can be further enhanced by combining VX-809 with other 
CFTR correctors, such as Corr-4a (Pedemonte et al., 2005) or VRT-
325 (Van Goor et al., 2006, 2011), or with CFTR potentiators, such as 
Ivacaftor (also known as VX-770; Van Goor et al., 2011). In clinical 
trials, VX-809 improved clinical measures of CFTR function and lung 
function when combined with the CFTR potentiator Ivacaftor (Van 
Goor et al., 2011; Clancy et al., 2012). The aim of this in vitro study 
was to determine the mechanism by which VX-809 modulates the 
folding pathway of CFTR to suppress misfolding of F508del-CFTR 
and other disease-related CFTR mutants.
RESULTS
VX-809 stabilizes N-terminal CFTR fragments that contain 
MSD1
For identification of regions of CFTR required for VX-809 activity, 
CFTR fragments of different lengths were expressed in HEK-293 
cells, and their steady-state accumulation and half-lives were quanti-
fied in biochemical assays (Figures 1, A and B, and Supplemental 
Figure S1). Because CFTR folding initiates cotranslationally and 
channel assembly is completed posttranslationally (Higgins, 1992), 
CFTR fragments, which may resemble folding intermediates, have 
been used to study CFTR biogenesis. The underlying rationale is 
that differences in accumulation or half-life between CFTR frag-
ments of different lengths are believed to reflect differences in the 
stability of the protein conformation and resistance to endoplasmic 
reticulum–associated degradation (ERAD). Consistent with this, 
CFTR fragments 370 and 530, which accumulated at markedly lower 
levels compared with CFTR 430 and CFTR 653, were more suscep-
tible to proteasome inhibition by bortezomib (Figure 1B). Differ-
ences in accumulation and half-life of CFTR fragments have been 
used successfully to identify Hsp70- and calnexin-dependent steps 
in CFTR folding and degradation pathways (Meacham et al., 1999; 
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potency or efficacy of VX-809, suggesting that neither of these resi-
dues was critical for binding of VX-809 to CFTR. Additional studies 
are now required to identify the VX-809 binding site in MSD1.
VX-809 suppresses folding defects in CFTR caused by 
disease-related mutations in MSD1
Data presented thus far suggest that MSD1 is the minimum-length 
fragment required for VX-809 action. There are several CF-associ-
ated mutations in MSD1 that cause defects in CFTR processing and 
function: N-terminal tail (E56K and P67L), TM1 (E92K), TM2 (L206W), 
and TM4 (V232D) (Figure 4, A–E). The severe folding (Figure 4, A–B) 
and functional (Figure 4E) defects exhibited by E56L, P67L and 
L206W were completely corrected by 5 μM VX-809. In contrast, 5 
μM VX-809 only partially restored folding and function to E92K and 
V232D (Figure 4, A and E). Interestingly, VX-809 demonstrated re-
duced potency for E92K-CFTR relative to F508del-CFTR, for both 
correcting folding and function (Figure 4, B and C), yet was able to 
fully restore E92K-CFTR at 30 μM. However, Corr4a could not re-
store E92K-CFTR function (Figure 4D).
V232D-CFTR was the least responsive to VX-809, and higher 
concentrations of the compound did not restore function beyond 
the 25% of normal CFTR observed in the presence of 5 μM VX-
809. Taken together with the observation that Corr4a restored 
proper folding of CFTR, and their deletion caused a biogenic defect 
that was not corrected by VX-809.
To determine whether residues 370–380 are critical for folding of 
MSD1 to a conformation that is sensitive to VX-809, we compared 
the resistance of CFTR 370 and CFTR 380 to digestion by trypsin 
(Figure 3C). CFTR 370 was completely digested by trypsin and was 
not protected by VX-809, whereas CFTR 380 adopted a conforma-
tion that is partially resistant to trypsin digestion and was protected 
from digestion by VX-809. Thus residues 371–380 are important for 
folding of MSD1 to a biochemically stable conformation. Once trans-
lation of CFTR past residue 375 occurs, all the forms of CFTR exam-
ined are biochemically stabilized by VX-809 (Figures 1–3 and S1).
Given that the extension of CFTR 373 by two residues confers 
sensitivity of MSD1 fragments to VX-809, residues F374 and L375 
might be involved in folding of CFTR to a conformation that is sensi-
tive to VX-809. Despite the severe biogenic defects exhibited by 
F374A-CFTR, L375A-CFTR, the double mutation F374A/L375A-
CFTR (Figure 3A), F374A-CFTR 380, and L375A-CFTR 380 (Figure 
3B), VX-809 almost completely suppressed the biogenic defects 
caused by the F374A and L375A mutations at the 5-μM concentra-
tion that maximally suppressed folding defects in F508del-CFTR 
(Figure 3, A and B). Thus, while residues 374 and 375 are important 
for CFTR folding, mutation of F374 and L375 does not alter the 
FIGURE 1: Stabilization of N-terminal regions of CFTR by VX-809. (A) Domain boundaries of CFTR fragments used in 
this study. (B) The impact of bortezomib (Bort, 10 μM) on the steady-state levels of N-terminal CFTR fragments 
expressed in HEK293 cells. Indicated CFTR fragments were generated via introduction of a stop codon after the 
specified residue. Respective fragments were detected by Western blot with an antibody against the N-terminal tail of 
CFTR. (C and D) The impact of VX-809 (5 μM) on CFTR fragment levels. (E) Dose response of CFTR 380 to VX-809. 
(F) Pulse–chase analysis of the impact of VX-809 on the half-life of [35S]CFTR 380. Data are representative of three 
experiments. See Materials and Methods for details.
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with an additional corrector to restore 
F508del-CFTR function to normal levels 
(Van Goor et al., 2011; Mendoza et al., 2012; 
Rabeh et al., 2012). Understanding the na-
ture of the defective folding step(s) that limit 
VX-809 efficacy on F508del-CFTR may aid 
in the development of such corrector com-
binations. The biogenic defects in F508del-
CFTR that might limit VX-809 efficacy in-
clude 1) defective assembly caused by 
increased thermodynamic instability of 
F508del-NBD1 relative to NBD1 (Wang 
et al., 2010) or 2) defective assembly of 
F508del-NBD1 into a complex with ICL4 of 
MSD2 caused by loss of the F508 side chain 
(Serohijos et al., 2008).
To determine the extent to which ther-
modynamic instability of F508del-NBD1 im-
pacts efficacy of VX-809 on F508del-CFTR, 
we examined the effect of VX-809 on a set 
of intragenic suppressor mutations that in-
crease the solubility of purified NBD1 and 
thereby partially suppress biogenic defects 
in F508del-CFTR (Teem et al., 1993; Pissarra 
et al., 2008; Amaral and Farinha, 2013). 
These mutations are termed solubilizing (S) 
mutations and were introduced into NBD1 
in different combinations (Figure 5A, S2 [F429S, Q637R] and S3 
[F429S, F494N, and Q637R]). VX-809 increased accumulation of the 
C-band of F508del-CFTR to around 14% of normal CFTR, and the S 
mutations by themselves have little impact on accumulation of the 
C-band of F508del-CFTR (Figure 5B). Yet, in the presence of VX-
809, the C-band of S2/F508del-CFTR and S3/F508del-CFTR accu-
mulated at up to 45% of normal (wild type; Figure 5B). Interestingly, 
the positive effect of S2 and S3 on F508del-CFTR biogenesis was 
abolished by the F374A mutation, as VX-809 could not drive high-
level accumulation of the folded C-band of F374A/S2/F508del-
CFTR or F374A/S3/F508del-CFTR. In addition, the F374A mutation 
hindered VX-809 from suppressing folding defects in F508del-
CFTR.
In experiments with CFTR, the S2 and S3 mutations by them-
selves increased C-band accumulation almost twofold, and this ef-
fect was blocked by F374A (Figure 5C). Yet, in contrast to results 
with F508del-CFTR, VX-809 restored accumulation of the C-form of 
F374A/S2-CFTR and F374A/S3-CFTR to levels of S2 CFTR and S3 
CFTR under control conditions.
Two important observations are to be drawn from these data. 
First, mutations in NDB1 that increase the thermodynamic stability 
of purified NBD1 (i.e., S2 or S3) also increase the efficacy of VX-809 
on F508del-CFTR. Therefore the thermodynamic instability of 
F508del-NBD1 limits the efficacy of VX-809 on F508del-CFTR. Sec-
ond, F374 is located in the cytosolic linker domain, positioned 
between TM6 and NBD1, required for folding of MSD1 to a confor-
mation that can be modulated by VX-809 (Figures 2 and 3). The 
folding defect caused by F374A is efficaciously corrected by 
VX-809 (Figure 3), but the F374A mutation blocks VX-809 action on 
F508del-CFTR. In addition, F374A also blocks the positive effect of 
S mutations on CFTR and F508del-CFTR biogenesis. Thus F374 
appears to facilitate interdomain communication between MSD1 
and NBD1, and, further, allosteric communication of structural 
information between MSD1 and NBD1 appears critical for VX-809 
correction of F508del-CFTR.
V232D-CFTR biogenesis and function to normal levels (Caldwell 
et al., 2011), these data suggest that correctors such as VX-809 
and Corr4a can act to selectively suppress folding defects in CFTR 
caused by different disease-related mutations in MSD1.
Because E92K-CFTR was corrected to normal levels of function 
but F508del was corrected to ∼15% of normal function, the impact 
of VX-809 on the double mutation E92K/F508del-CFTR was tested. 
(Figure 4B). The effect of VX-809 on the C-band of E92K/F508del-
CFTR was consistent with the dose response for E92K-CFTR, while 
the level of efficacy was consistent with that for F508del-CFTR. Thus 
the E92K mutation causes a folding defect in E92K/F508del-CFTR 
that requires a higher compound concentration, but the folding de-
fects caused by F508del limit the efficacy of VX-809. These data 
support the concept that VX-809 action on MSD1 aids in suppres-
sion of some but not all of the folding defects caused by ΔF508.
VX-809 is highly efficacious at correction of folding defects in 
CFTR caused by some, but not all, of the missense mutations in 
MSD1 that were evaluated. E92K is unique among these mutants, 
as it alters the potency of VX-809, yet the biogenic defects caused 
by this mutation are completely corrected by VX-809. Mutational 
analysis of E92 suggested that mutation of this residue disrupts a 
salt bridge in MSD1 that is required for CFTR folding (Figure S3). 
E92 may therefore not be directly involved in binding VX-809 and 
instead appears to be required for folding of MSD1 to a conforma-
tion that binds VX-809 with high affinity.
Interdomain communication is required for VX-809 
to enhance CFTR folding
VX-809 was efficacious at correcting the folding defects caused by 
missense mutations in MSD1, and its ability to stabilize MSD1 ap-
pears to partially suppress the folding defects caused by F508del 
from NBD1. Yet VX-809 efficacy was limited by folding defects that 
appear to occur downstream of its effects on MSD1. Because VX-
809 restored the function of some MSD1 CFTR mutants to normal 
levels in model cells, there is potential that it could act in concert 
FIGURE 2: Comparison trypsin-resistant fragments liberated from CFTR 380 and ΔF508-CFTR in 
the presence or absence of VX-809. CFTR 380 and ΔF508-CFTR were expressed in HEK293 cells 
in the absence or presence of VX-809 (5 μM). Cells were incubated 18 h in the presence of 
VX-809 and were lysed with PBS containing 1% Triton X-100. The indicated concentration of 
trypsin was added, and digestions were carried out on ice for 15 min. CFTR was detected via 
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productively interact with CFTR 837–1480 
(i.e., the C-band does not accumulate in the 
presence of F508del-CFTR 837). VX-809 in-
creased the accumulation of F508del-CFTR 
837 by several fold (Figure 6A, lane 5 vs. 
lane 6) but did not promote interactions be-
tween F508del-CFTR 837 and CFTR 837–
1480, as indicated by a lack of C-band 
(Figure 6A, lane 6).
Defective contacts between F508del-
NBD1 and ICL4 that limit F508del-CFTR as-
sembly have been partially restored by in-
troduction of the V510D mutation into 
NBD1 by permitting the formation of a salt 
bridge between D510 and R1070 of ICL4 
(Wang et al., 2007; Figure 6B). The V510D 
mutation partially corrects misfolding of 
F508del-CFTR, as shown by the C-band for 
V510D/F508del-CFTR (Figure 6B, lane 4), to 
levels similar to that for F508del-CFTR in the 
presence of VX-809. Remarkably, VX-809 
stimulated the accumulation C-band of 
V510D/ F508del-CFTR to the levels ob-
served for normal CFTR.
To determine whether formation of a salt 
bridge between D510 and R1070 was im-
portant for this effect, we introduced the 
R1070A mutation into V510D/F508del-
CFTR. In the presence of VX-809, the accu-
mulation of the C-band of R1070A/V510D/
F508del-CFTR was reduced by 75% relative 
to V510D/F508 -CFTR (Figure 6B, lane 7). 
Yet VX-809 was still able to increase folded 
R1070A/V510D/F508- CFTR to levels that 
were significantly higher than those for VX-
809–treated F508del-CFTR. Because the 
V510D mutation can modestly improve the 
thermodynamic stability of purified NBD1 
(Lewis et al., 2010; Wang et al., 2010), the 
residual VX-809 corrector function on 
R1070A/V501D/F508del-CFTR could result 
from thermodynamic stabilization of NBD1 
that would occur in the absence of salt-bridge formation between 
D510 and R1070.
Collectively these data are consistent with the concept that 
VX-809 action on MSD1 partially restores F508del-CFTR function 
through modulation of the protein conformation of MSD1. This ac-
tion of VX-809 appears to have global effects on the conformation 
of CFTR. However, to achieve higher levels of correction of F508del-
CFTR biogenesis by VX-809 requires either further stabilization of 
NBD1 and/or restoration of contacts between F508del-NBD1 and 
MSD2.
DISCUSSION
Data presented reveal that VX-809 acts early in CFTR biogenesis to 
modulate the conformation of MSD1 and thereby suppress folding 
defects in ΔF508-CFTR and disease-related MSD1 mutants. Correc-
tive conformational changes in MSD1 that are driven by VX-809 
appear to be communicated to other domains in CFTR via a mecha-
nism involving F374 in the linker domain that is located between 
TM6 and NBD1. VX-809 positively impacts the conformation of 
MSD1 to increase the efficiency of interactions between MSD1 with 
Stabilization of the NBD1:ICL4 interface increases VX-809 
efficacy on F508del-CFTR
Defective assembly of NBD1 into a complex with solvent-exposed 
residues on ICL4 hinders F508del-CFTR folding (Serohijos et al., 
2008). The extent to which this folding defect limits VX-809 efficacy 
(Figure 6) was tested by examining the ability of VX-809 to enhance 
the assembly of nonoverlapping N- and C-terminal CFTR fragments 
into a complex that can escape the ER (Figure 6A). Fragments of 
CFTR that contain the N- (1–837) and C- (837–1480) terminus as-
semble into a complex that folds, escapes the ER, and accumulates 
as a maturely glycosylated species (Rosser et al., 2008). Thus, if VX-
809 acts on MSD1 to positively impact TM segment assembly, VX-
809 would be expected to increase CFTR fragment assembly. Con-
sistent with previous results (Figures 1, 2, and S1), VX-809 does not 
increase accumulation of CFTR 837–1480 alone (Figure 6A, lanes 1 
and 2), but it did increase accumulation of CFTR 837. In addition, 
VX-809 stimulated the CFTR 837–dependent accumulation of C-
band by greater than twofold (Figure 6A, lane 3 vs. lane 4).
Deletion of F508 prevents accumulation of F508del-CFTR 837 
(Figure 6A, lane 3 vs. lane 5), and F508del-CFTR 837 does not 
FIGURE 3: CFTR amino acids 370–380 are required for folding of MSD1 to a conformation 
stabilized by VX-809. (A) Deletion of residues 371–375 causes a folding defect in CFTR that is 
insensitive to VX-809. (B) Mutation of residues 374 and 375 causes folding defects in CFTR 380 
that are suppressed by VX-809. (C) CFTR 380, but not CFTR 370, folds to a trypsin-resistant 
conformation that is stabilized by VX-809. (D) F374A L375A CFTR exhibits a folding defect that 
is not efficaciously suppressed by VX-809. Levels of indicated forms of CFTR expressed in 
HEK293 cells were detected by Western blot with N-terminal–tail antibody. (C) Cells were lysed 
with PBS that contained 1% Triton X-100 and the indicated concentration of trypsin, and 
digestions were carried out on ice for 15 min. Unless otherwise noted, VX-809 was 5 μM.
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acts downstream of VX-809 to effectively stabilize F508del-NBD1 
and/or restore contacts between ΔF508-NBD1 and MSD2 may lead 
to development of a corrector combination therapy to treat CF.
Evidence to support the conclusion that VX-809 partially corrects 
F508del-CFTR folding by altering the conformation of MSD1 is as 
follows: 1) VX-809 biochemically stabilizes CFTR fragments that con-
tain only MSD1. 2) VX-809 alters the conformation of MSD1 to pro-
tect it from proteolytic digestion with trypsin. 3) CFTR fragments 
fold to a conformation that is stabilized by VX-809 after biosynthesis 
of amino acid F374. F374 is located in the linker between MSD1 and 
NBD1 and helps stabilize MSD1 in conformation that is sensitive to 
VX-809. 4) VX-809 cannot overcome folding defects caused by the 
NBD1, MSD2, and NBD2, thereby restoring function to a portion of 
nascent F508del-CFTR.
VX-809 restores F508del-CFTR function to 15% of normal in lung 
cells from CF patients (Van Goor et al., 2011), and the data pre-
sented here suggest that the efficacy of the drug is impacted by the 
thermodynamic instability of ΔF508-NBD1 and defective interac-
tions between ΔF508-NBD1 and MSD2. This conclusion is sup-
ported by observations that the use of VX-809 in combination with 
approaches that either enhance the stability of NBD1 or stabilize the 
NBD1:ICL4 interface permit folded F508del-CFTR to accumulate at 
levels that are 50–100% of normal CFTR. Interestingly, in the ab-
sence of VX-809, the thermodynamic stabilization of NBD1 or resto-
ration of the NBD1:ICL4 interface has little impact on F508del-CFTR 
folding. Therefore VX-809 action on MSD1 primes F508del-CFTR 
for additional corrective events that permit high-level accumulation 
of its properly folded form. Identification of a small molecule that 
FIGURE 5: Interdomain communication between MSD1 and NBD1 is 
required for VX-809 to enhance biosynthetic processing of CFTR. 
(A) Schematic of CFTR showing the position of indicated amino acid 
residues and domains. (B) Mutation of F374A hinders the ability of 
misfolding suppressor mutations S2 and S3 to increase the efficacy of 
VX-809 on F508del-CFTR. (C) Mutation of F374A hinders the ability of 
S2 and S3 to increase accumulation of the folded C-band of CFTR. 
Data in panels B and C are from Western blots of cell extracts. S2 
(F429S, Q637R) and S3 (F429S, F494N, and Q637R) are mutations 
introduced into NBD1 to increase the thermodynamic stability of 
NBD1 and thereby increase CFTR and F508del-CFTR (B and C) folding 
efficiency (Pissarra et al., 2008; Teem et al., 1993). Panel are 
representations of three experiments. Quantitation is normalized to 
100% of total C-band for CFTR detected for wild type. Bands B and C 
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FIGURE 4: Functional defects in CFTR caused by disease-related 
mutations in MSD1 are suppressed by VX-809. (A) Folding defects 
caused by mutation of CFTR’s N-terminus are differentially 
suppressed by VX-809 (5 μM). (B) Dose-dependent correction of 
E92K-CFTR misfolding by VX-809. (C) Dose-dependent correction of 
E92K-CFTR function by VX-809. (D) VX-809 (30 μM) and Corr4a 
(15 μM) restore E92K-CFTR channel activity to different levels. 
(E) VX-809 is efficacious at restoration of Cl− channel function to 
forms of CFTR that have mutations in MSD1. Western blots of mutant 
CFTR levels in HEK293 are shown in (A) and (B). Results from 
electrophysiological measurements of forskolin-stimulated (10 μM) 
CFTR channel activity are shown in (A–C). CFTR was stably expressed 
in polarized FRT cells and cAMP-stimulated currents were measured in 
Ussing chambers. (E) VX-809 was 5 μM, except in the case of 
E92K-CFTR, for which it was 30 μM. (C–D): n = 3 ± SE.
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VX-809 on MSD1 has potential to promote high-level functional cor-
rection of CFTR in people with CF who harbor mutations other than 
F508del (Bobadilla et al., 2002). Indeed, the data presented here 
demonstrate that VX-809 restores significant levels of function to a 
number of rare CFTR mutations. The development of personalized 
corrector therapies to treat people with CF will likely require the 
identification of individual CFTR genotypes whose functional de-
fects can be suppressed by VX-809 monotherapy or combination 
therapy with additional correctors.
MATERIALS AND METHODS
Plasmids, antibodies, and reagents
CFTR expression plasmids pcDNA3.1(+)-CFTR and 
pcDNA3.1(+)ΔF508-CFTR have been described elsewhere 
(Meacham et al., 2001; Younger et al., 2006). CFTR constructs rep-
resenting CF disease–causing point mutants or truncated biogenic 
intermediates were made using the QuikChange protocol (Strata-
gene, Santa Clara, CA). The CFTR antibody used in this study was 
MM13-4 (N-terminal tail epitope) from Millipore, Darmstadt, Ger-
many. Use of VX-809 in experiments with cultured cells was previ-
ously described (Van Goor et al., 2011).
Cell culture and transfection
HEK293 cells from the American Type Culture Collection (Manassas, 
VA) were maintained in DMEM (Gibco, Grand Island, NY) supple-
mented with 1% fetal bovine serum (Thermoscientific, Waltham, 
MA) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomy-
cin; Gibco) at 37°C in an atmosphere of 5% CO2. Cell transfections 
were performed using Effectene reagent (Qiagen, Valencia, CA). 
The empty pcDNA3.1(+) vector was used to ensure equal micro-
gram quantities of DNA were used in all transfection reactions.
Analysis of CFTR biogenesis
CFTR steady-state levels. Steady-state levels of CFTR and its 
mutants were determined by Western blot analysis. HEK293 cells 
were transiently transfected with the indicated plasmids (Grove 
et al., 2011). The transfected cells were allowed to recover for ∼18 h 
before addition of DMEM and were then supplemented with VX-
809 or dimethyl sulfoxide (DMSO; control). The cells were incubated 
with the correctors for 24 h before being isolated for Western blot 
analysis. The harvested cells were diluted with 2× SDS sample buffer 
(100 mM Tris-HCl, pH 6.8, 4% SDS, 0.05% bromophenol blue, 20% 
glycerol), sonicated, and heated at 37°C prior to the proteins being 
resolved on SDS–PAGE gels. The proteins were transferred to 
nitrocellulose membranes, and the membranes were probed with 
the designated antibodies. Tubulin levels were monitored as a 
loading control.
CFTR processing efficiency. CFTR processing efficiency was 
measured by pulse–chase analysis (Grove et al., 2011). Transiently 
transfected HEK293 cells were allowed to recover for 18 h. The 
cells were then incubated with DMEM supplemented with VX-809 
or DMSO for 2 h. Next, cells were starved in methionine-free MEM 
(Sigma-Aldrich, St. Louis, MO) for 30 min, pulse labeled for 30 min 
with [35S]methionine (100 μCi/six wells; 1200 Ci/mmol; ICN 
Biomedicals, Costa Mesa, CA), and then chased for the indicated 
amount of time. VX-809 was also included in the media during 
these steps of the pulse–chase reaction. Cells were then lysed in 
phosphate-buffered saline (PBS) buffer supplemented with 1% 
Triton (PBS-T (1%), 1 mM phenylmethylsulfonyl fluoride, and 
complete protease inhibitor cocktail (Roche, Indianapolis, IN). 
Soluble lysates were obtained by centrifugation at 20,000 × g 
combined mutation of F374A and L375A but efficaciously sup-
presses folding defects caused by each individual mutation. VX-809 
can modulate the conformation of MSD1 in the vicinity of the inter-
face between MSD1 and NBD1.
VX-809 is highly efficacious at correcting disease-causing muta-
tions in CFTR MSD1, but also significantly restores folding of disease-
related mutations in CFTR ICL4 (He et al., 2013). Therefore a possible 
explanation of these data is that VX-809 also acts directly on the 
NBD1/ICL4 interface (He et al., 2013). However, several observations 
from the data presented herein support the interpretation that 
VX-809 acts on MSD1 to allosterically suppress the assembly defects 
in CFTR caused by ICL4 mutations through interdomain communica-
tion: 1) VX-809 has no detectable effect on thermally induced unfold-
ing of purified NBD1, so it does not appear to act directly on NBD1 
(see Supplemental Figure S2); 2) VX-809 has no impact on the accu-
mulation of a C-terminal CFTR fragment that contains MSD1 and 
NBD2, so it does not appear to directly modulate the conformation 
of MSD2; and 3) VX-809 enhances the assembly of CFTR 1–837 into 
a complex with CFTR 837–1480 and also increases the accumulation 
of F508del-CFTR 1–837 to the level of the normal CFTR control. Yet 
VX-809 was not able to suppress defects in F508del-CFTR 1–837 
assembly into a complex with CFTR 837–1480.
Data presented are consistent with the concept that correctors 
such as VX-809 modulate the conformation of a specific region of 
CFTR to enhance global protein folding and assembly (Lukacs and 
Verkman, 2012; Moniz et al., 2013). Because CFTR folding involves 
cooperative domain assembly (Du and Lukacs, 2009), the action of 
FIGURE 6: Restoration of contact between F508del-NBD1 and ICL4 
increases the efficacy of VX-809 in repair of F508del-CFTR misfolding. 
(A) VX-809 enhances assembly of CFTR 837 into a complex with CFTR 
837–1480, but cannot correct assembly defects caused by ΔF508 from 
CFTR 837. Bands B and C represent the ER-localized and plasma 
membrane–localized forms of CFTR 837–1480, respectively. 
(B) Introduction of the V510D suppressor mutation into NBD1 permits 
VX-809 to drive high-level folding of F508del-CFTR. B and C denote 
the ER-localized and plasma membrane forms of F508del-CFTR, 
respectively. (A and B) Western blots decorated with N-terminal–tail 
CFTR antibody. VX-809 was present at 5 μM.
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for 10 min. Lysates were normalized to contain the same total 
amount of protein. 35S-labeled CFTR was immuno precipitated 
by incubation with a polyclonal α-CFTR antibody directed against 
the N-terminus; this was followed by addition of a 50% protein 
G bead slurry. The beads were washed with PBS-T (1%) 
supplemented with 0.2% SDS, the bound CFTR was eluted with 
2× sample buffer, and the samples were heated at 55°C for 
10 min. The samples were analyzed by SDS–PAGE and visualized 
by autoradiography.
Limited Proteolysis of CFTR. The content of six wells of a six-well 
plate containing HEK293 cells were transfected with 1 μg of the 
indicated CFTR plasmid (Rosser et al., 2008). At 24 h posttransfection, 
the cells were harvested in citric saline and lysed in PBS-Tr (0.1%) for 
1 h at 4°C. Lysates were cleared by centrifugation at 20,000 rpm for 
10 min in a Beckman Allegra 64R centrifuge. Supernatants were 
removed, and total microgram quantities of protein were determined 
by the DC Bio-Rad protein determination assay (Hercules, CA). Cell 
lysates were then diluted to a concentration of 2 μg/ml, and trypsin 
was added at the indicated final concentrations. The cleavage 
reactions were incubated on ice for 15 min and were then quenched 
by addition of complete protease inhibitor (Roche) and trypsin 
inhibitor. Sample buffer was added to a final 1× concentration, and 
samples were run on 12.5% SDS–PAGE gels. Gels were transferred 
to nitrocellulose and probed with N-terminal–tail CFTR antibody 
(MM13-4 1:1000 dilution).
Coexpression of N-and C-terminal domains of CFTR. Cells were 
transfected with pcDNA3.Then, 1-CFTR837X (1 μg) and pcDNA3.1-
CFTR837–1480 (1 μg), individually or in combination, were used to 
evaluate the impact of VX-809 on the assembly of CFTR’s membrane 
domains (Rosser et al., 2008). Reactions were balanced with 
pcDNA3.1 such that all transfections were performed with equal 
microgram quantities of DNA. At 24 h posttransfection, cells were 
harvested with citric saline, diluted in 2× sample buffer, sonicated for 
10 s, and warmed to 37°C for 10 min prior to loading on 10% SDS–
PAGE gels. Proteins were transferred to nitrocellulose using a Bio-
Rad mini gel wet transfer apparatus. Blots were blocked in blocking 
buffer containing 10% fat-free milk and 0.1% Triton-X 100 in PBS 
and probed with α-CFTR monoclonal N-terminal tail (MM13-4 
1:1000 dilution).
Electrophysiology
Ussing chamber techniques with Fisher rat thyroid (FRT) cells that 
were stably transfected with the indicated form of CFTR were used 
to record the transepithelial current resulting from CFTR-mediated 
chloride transport (Van Goor et al., 2006, 2011). Standard conditions 
were utilized for Ussing chamber measurements of forskilin (10 μM)-
stimulated CFTR activity (Van Goor et al., 2006); for normal CFTR 
activity peaked at 205.5 μA/cm2.
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